242 related articles for article (PubMed ID: 27197066)
1. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller LD; Chou JA; Black MA; Print C; Chifman J; Alistar A; Putti T; Zhou X; Bedognetti D; Hendrickx W; Pullikuth A; Rennhack J; Andrechek ER; Demaria S; Wang E; Marincola FM
Cancer Immunol Res; 2016 Jul; 4(7):600-10. PubMed ID: 27197066
[TBL] [Abstract][Full Text] [Related]
2. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
3. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
[TBL] [Abstract][Full Text] [Related]
5. Identification of unanimous immune subtypes for different hormone receptor phenotypes of human breast cancer with potential prognostic significance.
Yu C; Zhou L; Zhang Q
Int Immunopharmacol; 2021 May; 94():107473. PubMed ID: 33611062
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
8. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
[TBL] [Abstract][Full Text] [Related]
9. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
10. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
12. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
[TBL] [Abstract][Full Text] [Related]
13. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
[TBL] [Abstract][Full Text] [Related]
16. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
Liu R; Zhang W; Liu ZQ; Zhou HH
Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.
Behring M; Ye Y; Elkholy A; Bajpai P; Agarwal S; Kim HG; Ojesina AI; Wiener HW; Manne U; Shrestha S; Vazquez AI
Cancer Med; 2021 Aug; 10(16):5712-5720. PubMed ID: 34189853
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
19. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
20. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]